Corymbiferin, a chemical compound, exhibits significant anti-diabetic properties by enhancing antioxidant capacity and carbohydrate metabolism in diabetic rodents. In addition, Corymbiferin promotes the improvement of histopathology in both the liver and pancreatic β cells.

The treatment with Corymbiferin (40 mg/kg; p.o.; male Wistar rats,) reduces the FBG level significantly, similar to the effect of positive metformin on the diabetic rats[1]. Corymbiferin (400 mg/kg; p.o.) also significantly reduces the blood glucose and shows a similar effect to metformin on oral glucose tolerance test (OGTT)[1].